Literature DB >> 10216086

Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells.

L M Pilarski1, E Pruski, J Wizniak, D Paine, K Seeberger, M J Mant, C B Brown, A R Belch.   

Abstract

Although the mechanism(s) underlying mobilization of hematopoietic progenitor cells (HPCs) is unknown, detachment from the bone marrow (BM) microenvironment and motility are likely to play a role. This work analyzes the motile behavior of HPCs and the receptors involved. CD34(+)45(lo/med)Scatterlo/med HPCs from granulocyte colony-stimulating factor (G-CSF)-mobilized blood and mobilized BM were compared with steady-state BM for their ability to bind hyaluronan (HA), their expression of the HA receptors RHAMM and CD44, and their motogenic behavior. Although RHAMM and CD44 are expressed by mobilized blood HPCs, function blocking monoclonal antibodies (MoAbs) identified RHAMM as a major HA binding receptor, with a less consistent participation by CD44. Permeabilization of mobilized blood HPCs showed a pool of intracellular (ic) RHAMM and a smaller pool of icCD44. In contrast, steady-state BM HPCs have significantly larger pools of icRHAMM and icCD44. Also, in contrast to mobilized blood HPCs, for steady-state BM HPCs, MoAbs to RHAMM and CD44 act as agonists to upregulate HA binding. The comparison between mobilized and steady-state BM HPCs suggests that G-CSF mobilization is associated with depletion of intracellular stores of HA receptors and modulates HA receptor usage. To confirm that mobilization alters the HA receptor distribution and usage by HPCs, samples of BM were collected at the peak of G-CSF mobilization in parallel with mobilized blood samples. HA receptor distribution of mobilized BM HPCs was closely matched with mobilized blood HPCs and different from steady-state BM HPCs. Mobilized BM HPCs had lower pools of icHA receptors, similar to those of mobilized blood HPCs. Treatment of mobilized BM HPCs with anti-RHAMM MoAb decreased HA binding, in contrast to steady-state BM HPCs. Thus, G-CSF mobilization may stimulate an autocrine stimulatory loop for HPCs in which HA interacts with basal levels of RHAMM and/or CD44 to stimulate receptor recycling. Consistent with this, treatment of HPCs with azide, nystatin, or cytochalasin B increased HA binding, implicating an energy-dependent process involving lipid rafts and the cytoskeleton. Of the sorted HPCs, 66% were adherent and 27% were motile on fibronectin plus HA. HPC adherence was inhibited by MoAbs to beta1 integrin and CD44, but not to RHAMM, whereas HPC motility was inhibited by MoAb to RHAMM and beta1 integrin, but not to CD44. This finding suggests that RHAMM and CD44 play reciprocal roles in adhesion and motility by HPCs. The G-CSF-associated alterations in RHAMM distribution and the RHAMM-dependent motility of HPCs suggest a potential role for HA and RHAMM in trafficking of HPCs and the possible use of HA as a mobilizing agent in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216086

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Hyaluronan stimulates mobilization of mature hematopoietic cells but not hematopoietic progenitors.

Authors:  Ingrid Schraufstatter; Naira Serobyan; Richard DiScipio; Natalia Feofanova; Irina Orlovskaya; Sophia K Khaldoyanidi
Journal:  J Stem Cells       Date:  2009

Review 2.  Of Cytometry, Stem Cells and Fountain of Youth.

Authors:  Dariusz Galkowski; Mariusz Z Ratajczak; Janusz Kocki; Zbigniew Darzynkiewicz
Journal:  Stem Cell Rev Rep       Date:  2017-08       Impact factor: 5.739

3.  RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy.

Authors:  Shlomo Nedvetzki; Erez Gonen; Nathalie Assayag; Reuven Reich; Richard O Williams; Robin L Thurmond; Jing-Feng Huang; Birgit A Neudecker; Fu-Sheng Wang; Fu-Shang Wang; Eva A Turley; David Naor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-13       Impact factor: 11.205

4.  Secretory products of breast cancer cells upregulate hyaluronan production in a human osteoblast cell line.

Authors:  Nandita Bose; Anna M Masellis
Journal:  Clin Exp Metastasis       Date:  2006-04-27       Impact factor: 5.150

Review 5.  Can host receptors for fungi be targeted for treatment of fungal infections?

Authors:  Scott G Filler
Journal:  Trends Microbiol       Date:  2013-06-21       Impact factor: 17.079

Review 6.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

7.  Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Authors:  Anirban Ghosh; Hemalatha Kuppusamy; Linda M Pilarski
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

Review 8.  Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

9.  The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.

Authors:  Sara R Hamilton; Shireen F Fard; Frouz F Paiwand; Cornelia Tolg; Mandana Veiseh; Chao Wang; James B McCarthy; Mina J Bissell; James Koropatnick; Eva A Turley
Journal:  J Biol Chem       Date:  2007-03-28       Impact factor: 5.157

Review 10.  Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Drug Resist Updat       Date:  2008-05-19       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.